Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India
· Delayed Price · Currency is INR 72.66
+1.81 (2.55%)
Mar 12, 2025, 3:29 PM IST
Balaxi Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 2,761 | 2,413 | 3,364 | 2,794 | 2,313 | 456.33 | Upgrade
|
| Revenue | 2,761 | 2,413 | 3,364 | 2,794 | 2,313 | 456.33 | Upgrade
|
| Revenue Growth (YoY) | 5.34% | -28.28% | 20.42% | 20.77% | 406.95% | 226.51% | Upgrade
|
| Cost of Revenue | 1,552 | 1,289 | 2,072 | 1,980 | 1,728 | 328.27 | Upgrade
|
| Gross Profit | 1,209 | 1,124 | 1,293 | 814.24 | 585.36 | 128.06 | Upgrade
|
| Selling, General & Admin | 827.61 | 656.74 | 727.32 | 312.19 | 160.86 | 45.99 | Upgrade
|
| Other Operating Expenses | -0.11 | -0.11 | -0.26 | -0.3 | -1.75 | -0.34 | Upgrade
|
| Operating Expenses | 848.54 | 677.62 | 744.58 | 317.02 | 162.45 | 45.72 | Upgrade
|
| Operating Income | 360.36 | 446.44 | 548.12 | 497.22 | 422.9 | 82.34 | Upgrade
|
| Interest Expense | -28.04 | -16.77 | -5 | -1.42 | -0.13 | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.02 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -32.79 | -32.79 | 18.65 | 49.42 | 20.5 | 5.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.41 | 6.21 | 7.46 | - | -0 | - | Upgrade
|
| EBT Excluding Unusual Items | 294.11 | 403.09 | 569.22 | 545.22 | 443.29 | 87.94 | Upgrade
|
| Other Unusual Items | 10.89 | -382.93 | - | - | - | - | Upgrade
|
| Pretax Income | 305.01 | 20.15 | 569.22 | 545.22 | 443.29 | 87.94 | Upgrade
|
| Income Tax Expense | 31.34 | 44.02 | 109.6 | 68.65 | 61.92 | 26.9 | Upgrade
|
| Net Income | 273.66 | -23.87 | 459.63 | 476.58 | 381.37 | 61.04 | Upgrade
|
| Net Income to Common | 273.66 | -23.87 | 459.63 | 476.58 | 381.37 | 61.04 | Upgrade
|
| Net Income Growth | - | - | -3.56% | 24.96% | 524.83% | 210.47% | Upgrade
|
| Shares Outstanding (Basic) | 55 | 51 | 50 | 50 | 50 | 38 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 51 | 51 | 50 | 50 | 38 | Upgrade
|
| Shares Change (YoY) | 7.02% | 1.69% | 1.23% | - | 32.96% | 147.40% | Upgrade
|
| EPS (Basic) | 5.02 | -0.46 | 9.16 | 9.53 | 7.63 | 1.62 | Upgrade
|
| EPS (Diluted) | 5.02 | -0.46 | 9.08 | 9.53 | 7.63 | 1.62 | Upgrade
|
| EPS Growth | - | - | -4.74% | 24.96% | 369.94% | 25.49% | Upgrade
|
| Free Cash Flow | - | 41.74 | -69.83 | 288.23 | -12.74 | -142.19 | Upgrade
|
| Free Cash Flow Per Share | - | 0.81 | -1.38 | 5.76 | -0.25 | -3.78 | Upgrade
|
| Dividend Per Share | - | - | - | 0.100 | - | - | Upgrade
|
| Gross Margin | 43.78% | 46.58% | 38.42% | 29.14% | 25.30% | 28.06% | Upgrade
|
| Operating Margin | 13.05% | 18.50% | 16.29% | 17.80% | 18.28% | 18.04% | Upgrade
|
| Profit Margin | 9.91% | -0.99% | 13.66% | 17.06% | 16.49% | 13.38% | Upgrade
|
| Free Cash Flow Margin | - | 1.73% | -2.08% | 10.32% | -0.55% | -31.16% | Upgrade
|
| EBITDA | 380.7 | 465.57 | 565.64 | 502.34 | 425.88 | 82.41 | Upgrade
|
| EBITDA Margin | 13.79% | 19.29% | 16.81% | 17.98% | 18.41% | 18.06% | Upgrade
|
| D&A For EBITDA | 20.34 | 19.14 | 17.53 | 5.12 | 2.98 | 0.08 | Upgrade
|
| EBIT | 360.36 | 446.44 | 548.12 | 497.22 | 422.9 | 82.34 | Upgrade
|
| EBIT Margin | 13.05% | 18.50% | 16.29% | 17.80% | 18.28% | 18.04% | Upgrade
|
| Effective Tax Rate | 10.28% | 218.44% | 19.25% | 12.59% | 13.97% | 30.59% | Upgrade
|
| Revenue as Reported | 2,723 | 2,386 | 3,391 | 2,844 | 2,336 | 462.27 | Upgrade
|
| Advertising Expenses | - | 6.55 | 8.41 | 10.21 | 1.02 | 1.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.